Sosei Subsidiary Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-Class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

TOKYO–(BUSINESS WIRE)–Positive results from Phase 1b clinical trial with HTL9936, a first-in-class selective muscarinic M1 receptor agonist for improving cognition in dementia and schizophrenia
Source: BusinessWire-Primary

Sosei Subsidiary Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-Class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia